Dermatology Times' Sunday Crossword: March 30, 2025

Welcome to Dermatology Times' Sunday Crossword, where dermatology knowledge meets fun! Each week, we curate a selection of words and terms pulled directly from the latest news in the dermatology world. Whether it's breakthrough treatments, new research findings, or emerging trends, this crossword serves as both a challenge and an opportunity to reinforce your expertise in the field.

For more in-depth insights, don't forget to check out our Weekly Roundup, where we break down the most important stories and updates from the past week. And to stay ahead of the curve and prepare for future crosswords, make sure to follow our content throughout the week.

Try out either our interactive crossword or a static/non-interactive version below.

Interactive Crossword

This crossword was created with CrosswordLabs.com.

Static/Non-Interactive Crossword

Across

4. A novel once-weekly topical acne treatment that met primary endpoints.

5. A topical antibiotic linked to contact allergies in a recent study.

6. Skin cancer associated with significant psychological distress.

9. Used in a shampoo formulation showing efficacy against seborrheic dermatitis.

11. The bioactivity of this compound was studied in combination with moisturization.

Down

1. Antifungal compared to a silver nanoparticle shampoo for seborrheic dermatitis.

2. A key ingredient in a fixed-dose acne treatment gel tested in Hispanic patients.

3. A treatment evaluated in the DELTA 3 study for chronic hand eczema.

7. Gene-editing technology enhanced by nanoneedles for RDEB treatment.

8. A cytokine targeted by biologics to reduce infections in older patients with psoriatic disease.

10. Type of dermatitis that CBD and CBG ointments showed improvements in.

For answers to this week's puzzle, check out next week's edition of the Dermatology Times Sunday Crossword.

Answers from our March 23, 2025 puzzle: [Across: 4 - melanoma; 7 - keratolytic; 9 - HS; 10 - tezepelumab; Down: 1 - picosecond; 2 - psoriasis; 3 - zasocitinib; 5 - estrogen; 6 - dupilumab; 8 - TSW]